Market Update Economic Events Directors Deals Commodities Prices News Market Movers

Hvivo's influenza treatment shows positive result

Monday, 18th June 2018
Drug company Hvivo revealed Monday positive results from the Phase IIb field study after its influeza treatment met its primary and secondary goals.

Primary and secondary endpoints of the study was achieved after showing long-lasting T and B cell immunological responses, reducing influenza infection rates and the severity and duration of symptoms, hViVo said.

Based on the results of two Phase IIb trials and previous studies, the company's influeza treatment, FLU-v, was now ready for Phase III development, Hvivo said.

'It is our view that FLU-v is now positioned to enter Phase III, with clear disease and symptom-based endpoints identified,' said Trevor Phillips, Executive Chairman of Hvivo.

At 8:38am: (LON:HVO) hVIVO Plc share price was +5.3p at 25p

Story provided by

Related Shares: Hvivo

Share Search
Share Search Share Search

Visit the Share Search.
Share Search

Share News
Share News will do their best to ensure the quality of the information displayed on this site, but all information is provided as-is, free of charge. We cannot be held responsible for any loss, material or otherwise, due to incorrect information found here. UK data supplied by NBTrader and Digital Look. Share Prices are at least 15 minutes delayed.